Plasma amyloid-β composite biomarker
Biomarker1 paper1 finding
- Human trial1
Associations
1Konjac glucosylceramides
downin humans1Low certainty
1 study
Konjac glucosylceramides
downin humans1Low certainty
Konjac glucosylceramides are associated with plasma amyloid-β composite biomarker in humans.
Human triallow baseline amyloid burden5.4 mg/day24 weeksn = 40
Effects of Konjac glucosylceramides on cognitive function in cognitively unimpaired older adults with subjective cognitive concerns: a randomized, double-blind, controlled pilot study · The journal of nutrition, health & aging · 9 Sep 2026
Latest
1The Journal of Nutrition, Health & AgingHuman trial